Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to ...

Digital eyestrain or computer vision syndrome is real, increasing in prevalence and severity, and is a causative factor in ...

UAB School of Optometry researchers have secured a patent for a novel lens design that could slow myopia progression in ...

When it comes to myopia, most parents are aware that it is not just about getting a new pair of glasses every year. There are ...

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its ...

Add Yahoo as a preferred source to see more of our stories on Google. In late September the U.S. Food and Drug Administration made an announcement that has the potential to positively impact tens of ...

Prior to this approval, the only other device indicated for slowing pediatric myopia progression was a contact lens. The Food and Drug Administration (FDA) has cleared the Essilor Stellest eyeglass ...

SPRINGFIELD, Mo. (KY3) - Myopia or nearsightedness is a common vision problem that often begins between the ages of 6 and 14. Contacts or glasses can usually correct it, but new specialized lenses ...

SHERMAN OAKS, CA, UNITED STATES, March 9, 2026 /EINPresswire.com/ — As screen use, reading, and other near-vision demands remain part of daily life for many ...

An increase in myopia progression was observed among Chicago-area children early in the COVID-19 pandemic, reported researchers, who suggested that closure of schools and cancelling of activities may ...

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with those using placebo or 0.01% atropine, though they had higher rates of ...